Healthcare / BiotechnologyNasdaqGM
$1.56
-0.04 (-2.50%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-65.3M · quality 68.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
27/100
D
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$67M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-69.2%
↓Gross Margin
N/A
•Debt/Equity
0.02
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2025 · 4 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.84x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-77.9M · FCF $-65.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Net Income | $-77.9M | $-77.9M | $-80.6M | $-60.4M | $-31.2M | $-16.2M |
| EBITDA | $-82.8M | $-82.8M | $-88.2M | $-66.6M | $-32.3M | — |
| EPS | — | — | -2.38 | -2.74 | -7.56 | -9.32 |
| Balance Sheet | ||||||
| Debt/Equity | 0.02 | 0.02 | 0.02 | 0.04 | 0.03 | — |
| Current Ratio | 8.98 | 8.98 | — | — | — | — |
| Cash Flow | ||||||
| Free Cash Flow | $-65.3M | $-65.3M | $-68.4M | $-43.9M | $-32.3M | $-14.2M |
| Returns | ||||||
| ROE | -69.2% | -69.2% | -45.6% | -49.8% | -18.3% | 68.2% |
| Valuation | ||||||
| P/B | 0.44 | 0.44 | 1.27 | 0.83 | 0.28 | — |
| Growth & Yield | ||||||
| EPS Growth | — | — | 13.1% | 63.8% | — | — |
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+48.6%
Start / end P/E
n/dx → n/dx
EPS bridge
-2.38 → n/d
Residual
+48.6%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.